GUIDELINES FOR PERINATAL TESTING and ADMINISTRATION OF WINRHO® SDF (Rh IMMUNE GLOBULIN)

The Manitoba Rh Clinical Program Guidelines reflect the current recommended standards and are consistent with other Canadian and American Prenatal Testing Programs. The Fetal Assessment Unit is notified of all high risk mothers who have clinically significant red cell antibodies. It remains the responsibility of the referring physician to refer the patient to the Fetal Assessment Unit.

1. REQUISITIONS
   - Sample(s) from each mother, father or cord blood submitted MUST be accompanied by its own requisition.
   - Use the CBS Request for Perinatal Testing form (Rh.101) for mother and father samples.
   - Use the blue CBS Request for Cord / Neonate Blood Testing form (Rh.105) for cord or neonate samples.

2. SAMPLES
   - Mother and/or Father – 2 EDTA tubes (lavender top)
   - Cord Blood – 1 EDTA tube (lavender top)

3. GUIDELINES FOR PERINATAL TESTING

<table>
<thead>
<tr>
<th>Rh Unknown, First Pregnancy</th>
<th>Initial Visit</th>
<th>Father</th>
<th>26 – 28 Weeks</th>
<th>Post Partum</th>
<th>Cord Blood</th>
<th>As Requested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rh Unknown, First Pregnancy</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subsequent Pregnancy, Rh (D) Positive and Previous CBS Report On File</td>
<td>X</td>
<td>If requested</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Rh Negative</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinically Significant Antibodies Detected</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

** 28 weeks or additional samples may be submitted for patients at increased risk of allo-immunization (previous transfusion, fetal trauma or procedure, IV drug use)

Refer to this link: [https://blood.ca/en/hospitals/winnipeg-centre/Perinatal-Services](https://blood.ca/en/hospitals/winnipeg-centre/Perinatal-Services) for the tests performed and additional information.

4. GUIDELINES FOR ADMINISTRATION OF WINRHO® SDF (Rh IMMUNE GLOBULIN / RhIG)

I. Administer WinRho® SDF Rh Immune Globulin to Rh (D) negative women who do NOT have Anti-D antibodies
   - 28-30 Weeks
   - Give 1500 International Units (300 micrograms) RhIG (WinRho® SDF) by intravenous route.
   - 39-40 Weeks
   - Give 1500 International Units (300 micrograms) RhIG (WinRho® SDF) by intravenous route.

Ante-Partum Events such as Bleeding, Abdominal Trauma, Amniocentesis or Other Invasive Procedures
   - Give 1500 International Units (300 micrograms) RhIG (WinRho® SDF) by intravenous route and
   - For ongoing vaginal bleeding give an additional 1500 International Units (300 micrograms) RhIG (WinRho® SDF) every 12 weeks until delivery.

Post-Partum
   - Includes events such as spontaneous or therapeutic abortion, ectopic pregnancy, stillbirth, intra-uterine death, molar pregnancies.
   - Give 1500 IU (300 micrograms) RhIG (WinRho® SDF) by intravenous route if the infant is Rh (D) positive or the Rh is unknown.

Revised 02/2014
4. GUIDELINES FOR ADMINISTRATION OF WINRHO® SDF (CONTINUED)

II. RhIG (WinRho® SDF) is NOT indicated for Rh (D) Negative women when:
   • The fetus is Rh (D) negative.
   • The mother has anti-D antibodies.
   • The mother has delivered and she received 1500 IU (300 micrograms) RhIG (WinRho® SDF) at 39-40
     weeks.

III. Administration
   • Administer RhIG (WinRho® SDF) within 72 hours of event (refer to section I above) to ensure
     effectiveness.
   • If treatment is delayed, give the injection up to 28 days after the event, with the understanding of a
     lower likelihood of protection.
   • Collect blood samples prior to administering RhIG (WinRho® SDF). Ensure the blood does not come
     into contact with needles used to reconstitute the RhIG (WinRho® SDF).
   • Administer RhIG (WinRho® SDF) by intravenous route to ensure maximum efficacy.
   • The attending physician/midwife will be notified if additional RhIG (WinRho® SDF) is required post-
     partum based on the results of the Quantitative Fetal Red Cell Detection (Kleihauer-Betke) testing.

NOTE: RhIG (WinRho® SDF) is a blood product and your facility’s policies for the administration of blood products
must be followed.

REFERENCES: